Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Radin

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
European Journal of Pharmacology|February 1, 2025
Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjectsDaniel P Radin, Rok Cerne, Jodi L Smith, et al.
Future Medicinal Chemistry|September 20, 2024
Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763Daniel P Radin, Sheng Zhong, Rok Cerne, et al.
Frontiers in Oncology|May 2, 2022
Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth <i>In Vivo</i>Daniel P Radin, Gregory Smith, Victoria Moushiaveshi, et al.
Current Alzheimer Research|February 11, 2025
Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic StrokeDaniel P Radin, Sheng Zhong, Rok Cerne, et al.
Pharmacology, Biochemistry, and Behavior|February 2, 2025
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to todayDaniel P Radin, Arnold Lippa, Sabhya Rana, et al.
Pharmacology & Therapeutics|November 9, 2024
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategySabhya Rana, Anna F Fusco, Jeffrey M Witkin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2024
Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In VivoDaniel P Radin, Sophie Shifman, Ian R Outhwaite, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 19, 2025
Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastomaSophie G Shifman, Jennifer L O'Connor, Daniel P Radin, et al.
Biochemical Pharmacology|May 19, 2024
AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefitJeffrey M Witkin, Daniel P Radin, Sabhya Rana, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
European Journal of Pharmacology|February 1, 2025
Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjectsDaniel P Radin, Rok Cerne, Jodi L Smith, et al.
Future Medicinal Chemistry|September 20, 2024
Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763Daniel P Radin, Sheng Zhong, Rok Cerne, et al.
Frontiers in Oncology|May 2, 2022
Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth <i>In Vivo</i>Daniel P Radin, Gregory Smith, Victoria Moushiaveshi, et al.
Current Alzheimer Research|February 11, 2025
Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic StrokeDaniel P Radin, Sheng Zhong, Rok Cerne, et al.
Pharmacology, Biochemistry, and Behavior|February 2, 2025
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to todayDaniel P Radin, Arnold Lippa, Sabhya Rana, et al.
Pharmacology & Therapeutics|November 9, 2024
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategySabhya Rana, Anna F Fusco, Jeffrey M Witkin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 31, 2024
Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In VivoDaniel P Radin, Sophie Shifman, Ian R Outhwaite, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 19, 2025
Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastomaSophie G Shifman, Jennifer L O'Connor, Daniel P Radin, et al.
Biochemical Pharmacology|May 19, 2024
AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefitJeffrey M Witkin, Daniel P Radin, Sabhya Rana, et al.
Pageof 3